Why Elevated PSA Results Get Missed in Primary Care

Elderly man in a hospital gown resting in a hospital bed with a nasal cannula, pulse oximeter, and IV line.
|

An elevated PSA result doesn’t diagnose prostate cancer, but it warrants clinical review and a documented plan. A result can have a noncancer explanation and still need to be reviewed, communicated, and addressed.

For patients and families looking back after a prostate cancer diagnosis, the central question is often not whether one test should have produced an immediate diagnosis. It is whether the medical record shows a reasonable response to the abnormal result. At Crowe & Harris, LLP, our attorneys examine those clinical records to identify breakdowns in primary care communication and follow-up.

If you or a loved one experienced a delayed prostate cancer diagnosis after an abnormal lab test, contact Crowe & Harris, LLP to discuss your potential claim. Call (617) 404-3417 today to schedule a confidential consultation with our legal team.

What an Elevated PSA Does & Doesn’t Show

PSA, short for prostate-specific antigen, is a protein measured through a blood test. A higher level can be associated with prostate cancer, but benign prostatic hyperplasia and prostatitis can also cause an increase. Infection, inflammation, and recent sexual activity can affect the result as well.

An elevated number should therefore be neither treated as proof of cancer nor dismissed as harmless. Evidence-based clinical guidance recommends confirming the result with repeat PSA testing before moving to further diagnostic evaluation. Prior results, the patient’s age, and the reason for testing inform the next step.

Screening itself is a separate decision. The U.S. Preventive Services Task Force recommends that men ages 55 through 69 make an individual decision about periodic PSA-based screening after discussing potential benefits and harms with a clinician. It recommends against routine PSA-based screening for men age 70 and older.

How Abnormal PSA Results Go Unaddressed

Breakdowns in result management are often administrative as well as clinical. A test may be ordered during a routine visit and released to an electronic chart without documented review, patient communication, a repeat order, or a referral plan.

A Harvard Risk Management Foundation case study described a delayed diagnosis of prostate cancer after a physician said they had not seen the abnormal PSA result. Ordering a laboratory test and acting on its result are separate steps. A portal notification alone doesn’t show that the patient understood the result or that the clinician established an appropriate next action.

A 10-year retrospective study found that more than one-third of patients in primary care with an elevated PSA had incomplete follow-up within two years of the initial abnormal test.

Practices can reduce missed-result risks by clearly flagging results, assigning responsibility for review, and escalating a result when no action is recorded within a set period. When examining a past concern, the key issue is whether the chart identifies who reviewed the result and what happened next.

Clinical Steps After an Abnormal PSA

No single PSA number or deadline applies to every patient. The appropriate response depends on factors such as age, prior readings, and plausible noncancer causes of the elevation.

An initial evaluation often includes a digital rectal exam, or DRE, in which the clinician checks the prostate for abnormalities through the rectum. The clinician should also assess possible causes such as infection, inflammation, prostatitis, or benign prostatic hyperplasia before deciding what should happen next.

Depending on the circumstances, the clinical sequence includes:

  • Reviewing the initial PSA result alongside earlier results and the patient’s history.
  • Repeating the PSA test to determine whether the elevation persists.
  • Documenting the discussion with the patient and the plan for additional monitoring or evaluation.
  • Making a urology referral when continued elevation, examination findings, symptoms, or other circumstances warrant further assessment.

In the Harvard risk-management case, the standard of care described at that time was to repeat the PSA within three months and refer the patient to urology if the result remained elevated. That case-specific timeline isn’t a universal rule. An unexplained gap without repeat testing, a documented discussion, or a referral can nevertheless be significant when reviewing a delayed cancer diagnosis.

Records That Can Clarify a Possible Delay

Evaluating a possible delay requires a timeline, not just the first abnormal laboratory value. A later diagnosis doesn’t automatically mean the earlier care was improper, and a documented plan may show that clinicians acted reasonably even if cancer wasn’t identified at the first opportunity. The broader context is significant: prostate cancer was reported in 266,307 people in the United States in 2023, and 34,815 men died from the disease in 2024.

Records may reveal that an abnormal result wasn’t acknowledged, a planned repeat test didn’t occur, or a referral wasn’t completed. Useful records and dates to gather include:

  • The date the PSA test was ordered and the date the laboratory reported the result.
  • Office notes, portal messages, letters, telephone logs, and medication records reflecting communication about the result.
  • Dates of repeat PSA testing, digital rectal exams, urology referrals, imaging, biopsy, and the eventual diagnosis.
  • Records of symptoms, including frequent urination, pain during urination, blood in the urine, or difficulty starting or stopping urination.

Request complete records from the practice that ordered the test, the laboratory, the urologist, and the hospital involved in the patient’s care. A chronological file is more useful than isolated documents because it shows whether each recommended step was completed or merely discussed.

When a Delay Raises a Medical Malpractice Question

A medical malpractice claim requires more than an elevated PSA or a cancer diagnosis. The review considers whether the care departed from the applicable standard of care, whether that departure caused a meaningful delay, and whether the delay caused additional harm. These questions generally require careful analysis of the records and medical opinions.

In Massachusetts, medical malpractice claims generally must be filed within three years after the cause of action accrues under the discovery standard. The law also generally bars claims filed more than seven years after the alleged negligent act or omission, subject to a limited foreign-object exception. A medical malpractice tribunal made up of a judge, physician, and attorney reviews whether sufficient evidence supports the claim before it proceeds toward trial.

Our Cancer Misdiagnosis review process includes:

  • Examining medical records for adherence to the standard of care.
  • Identifying possible negligence.
  • Consulting medical professionals.
  • Evaluating losses.
  • Addressing insurance communications and legal deadlines.

Founding Partner Philip J. Crowe has been licensed since 1969, and our senior partners are actively involved in our team-based case handling.

If you have questions about a delayed prostate cancer diagnosis, Crowe & Harris, LLP offers free consultations at (617) 404-3417.